SLC29A1 and Huntington disease: Recent studies suggest that reduced extracellular nucleotide breakdown and reduced glycolysis might contribute to the pathology of HD (Toczek et al., 2018; HD iPSC Consortium, 2020) and that ENT1 could be a therapeutical target for this disease (Kao et al., 2017).